The Desmoid Tumor Research Foundation

January 2021

Prognostic significance of CTNNB1 mutation in recurrence of sporadic desmoid tumors

Author Information

Guo L(1), Wang X(2), Xu B(2), Lang R(3), Hu B(1).

(1)Dept of Thoracic Surgery, Beijing Chaoyang Hospital, Capital Medical Univ, Beijing, China. (2)Pharmacy Dept, Beijing Chao-Yang Hospital, Capital Medical Univ, Beijing, China. (3)Dept of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical Univ, Beijing, China.

Publication

Future Oncol

Summary

The goal of this meta-analysis was to evaluate the association between CTNNB1 mutation and recurrence in surgically treated desmoid tumor (DT) patients. PubMed, Embase and Cochrane library were systematically searched. The outcome of interest was the risk of recurrence. The number of patients with CTNNB1 mutation and the number of recurrences they developed were recorded and compared. The quality of these studies was assessed using the Newcastle-Ottawa Quality Assessment Scale. Odds ratios and variances were calculated and pooled. A total of eight studies were identified including 637 patients. S45F-mutated DTs were more likely to recur compared with wild type, T41A and other mutated DTs. However, there were no statistically significant differences in the rate of recurrence between wild type and T41A mutation or other mutation. Among CTNNB1 mutations, the mutation S45F is a high-risk factor for recurrence of DT and may be a predictive marker for the recurrence of sporadic DT.

View Abstract